![ALPN-202](https://www.adcreviews.com/wp-content/uploads/2022/10/ALPN-202-240x118.jpg)
Two patients died, CD28/PD-L1/CTLA-4 triple immunotherapy clinical trial terminated
On October 24, Alpine Immune Sciences announced that it had terminated two clinical trials of the conditional CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor davoceticept